Low liver stiffness among cirrhotic patients with hepatitis B after prolonged treatment with nucleoside analogs

Ellen Sloth Andersen; Ola Weiland; Peter Leutscher; Henrik Bygum Krarup; Johan Westin; Belinda Moessner; Zbigniew Konopski; Svein-Oskar Frigstad; Mette Kjær; Peer Brehm Christensen; Nina Margrethe Weis

doi:10.3109/00365521.2011.565068

Low liver stiffness among cirrhotic patients with hepatitis B after prolonged treatment with nucleoside analogs

Ellen Sloth Andersen, Ola Weiland, Peter Leutscher, Henrik Bygum Krarup, Johan Westin, Belinda Moessner, Zbigniew Konopski, Svein-Oskar Frigstad, Mette Kjær, Peer Brehm Christensen, Nina Margrethe Weis

Department of Clinical Medicine

14 Citations (Scopus)

Abstract

Objective. Case reports and short-term clinical trials have suggested that treatment for chronic hepatitis B (CHB) may lead to improvement of cirrhosis. The aim of the present study was to measure liver stiffness in patients diagnosed with advanced fibrosis or cirrhosis prior to prolonged treatment with nucleoside or nucleotide analogs (NUCs) for CHB. Materials and methods. Patients with CHB and advanced fibrosis or cirrhosis prior to treatment with NUCs for at least 1 year were offered inclusion in the study. We measured liver stiffness using transient elastography (TE) at follow-up. TE cut-off levels to Metavir classification for fibrosis stage F2, F3 and F4 were ≥7.2 kPa, ≥8.1, and ≥11.0 kPa, respectively. Results. Among 66 patients with a successful TE examination at follow-up, 53 patients (80%) had cirrhosis and 13 had (20%) advanced fibrosis (F3) prior to treatment. Median treatment duration was 50.5 months. Among patients with cirrhosis prior to treatment, 26 (49%) had liver stiffness below 11.0 kPa at follow-up, suggesting regression of cirrhosis. Among patients with advanced fibrosis (F3) prior to treatment, 10 (77%) had liver stiffness below 8.1 kPa after treatment, suggesting improvement of fibrosis. Conclusion. Transient elastography examinations demonstrate that prolonged treatment with NUCs in patients with CHB results in low liver stiffness, suggesting regression of fibrosis in a majority of patients with advanced fibrosis or cirrhosis.

Original language	English
Journal	Scandinavian Journal of Gastroenterology
Volume	46
Issue number	6
Pages (from-to)	760-6
Number of pages	7
ISSN	0036-5521
DOIs	https://doi.org/10.3109/00365521.2011.565068
Publication status	Published - Jun 2011

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3109/00365521.2011.565068

Cite this

Andersen, E. S., Weiland, O., Leutscher, P., Krarup, H. B., Westin, J., Moessner, B., Konopski, Z., Frigstad, S-O., Kjær, M., Christensen, P. B., & Weis, N. M. (2011). Low liver stiffness among cirrhotic patients with hepatitis B after prolonged treatment with nucleoside analogs. Scandinavian Journal of Gastroenterology, 46(6), 760-6. https://doi.org/10.3109/00365521.2011.565068

Andersen, ES, Weiland, O, Leutscher, P, Krarup, HB, Westin, J, Moessner, B, Konopski, Z, Frigstad, S-O, Kjær, M, Christensen, PB & Weis, NM 2011, 'Low liver stiffness among cirrhotic patients with hepatitis B after prolonged treatment with nucleoside analogs', Scandinavian Journal of Gastroenterology, vol. 46, no. 6, pp. 760-6. https://doi.org/10.3109/00365521.2011.565068

@article{4156552f52bf467880b6a5479dcf16d8,

title = "Low liver stiffness among cirrhotic patients with hepatitis B after prolonged treatment with nucleoside analogs",

abstract = "Objective. Case reports and short-term clinical trials have suggested that treatment for chronic hepatitis B (CHB) may lead to improvement of cirrhosis. The aim of the present study was to measure liver stiffness in patients diagnosed with advanced fibrosis or cirrhosis prior to prolonged treatment with nucleoside or nucleotide analogs (NUCs) for CHB. Materials and methods. Patients with CHB and advanced fibrosis or cirrhosis prior to treatment with NUCs for at least 1 year were offered inclusion in the study. We measured liver stiffness using transient elastography (TE) at follow-up. TE cut-off levels to Metavir classification for fibrosis stage F2, F3 and F4 were ≥7.2 kPa, ≥8.1, and ≥11.0 kPa, respectively. Results. Among 66 patients with a successful TE examination at follow-up, 53 patients (80%) had cirrhosis and 13 had (20%) advanced fibrosis (F3) prior to treatment. Median treatment duration was 50.5 months. Among patients with cirrhosis prior to treatment, 26 (49%) had liver stiffness below 11.0 kPa at follow-up, suggesting regression of cirrhosis. Among patients with advanced fibrosis (F3) prior to treatment, 10 (77%) had liver stiffness below 8.1 kPa after treatment, suggesting improvement of fibrosis. Conclusion. Transient elastography examinations demonstrate that prolonged treatment with NUCs in patients with CHB results in low liver stiffness, suggesting regression of fibrosis in a majority of patients with advanced fibrosis or cirrhosis.",

author = "Andersen, {Ellen Sloth} and Ola Weiland and Peter Leutscher and Krarup, {Henrik Bygum} and Johan Westin and Belinda Moessner and Zbigniew Konopski and Svein-Oskar Frigstad and Mette Kj{\ae}r and Christensen, {Peer Brehm} and Weis, {Nina Margrethe}",

year = "2011",

month = jun,

doi = "10.3109/00365521.2011.565068",

language = "English",

volume = "46",

pages = "760--6",

journal = "Scandinavian Journal of Gastroenterology",

issn = "0036-5521",

publisher = "Taylor & Francis",

number = "6",

}

TY - JOUR

T1 - Low liver stiffness among cirrhotic patients with hepatitis B after prolonged treatment with nucleoside analogs

AU - Andersen, Ellen Sloth

AU - Weiland, Ola

AU - Leutscher, Peter

AU - Krarup, Henrik Bygum

AU - Westin, Johan

AU - Moessner, Belinda

AU - Konopski, Zbigniew

AU - Frigstad, Svein-Oskar

AU - Kjær, Mette

AU - Christensen, Peer Brehm

AU - Weis, Nina Margrethe

PY - 2011/6

Y1 - 2011/6

N2 - Objective. Case reports and short-term clinical trials have suggested that treatment for chronic hepatitis B (CHB) may lead to improvement of cirrhosis. The aim of the present study was to measure liver stiffness in patients diagnosed with advanced fibrosis or cirrhosis prior to prolonged treatment with nucleoside or nucleotide analogs (NUCs) for CHB. Materials and methods. Patients with CHB and advanced fibrosis or cirrhosis prior to treatment with NUCs for at least 1 year were offered inclusion in the study. We measured liver stiffness using transient elastography (TE) at follow-up. TE cut-off levels to Metavir classification for fibrosis stage F2, F3 and F4 were ≥7.2 kPa, ≥8.1, and ≥11.0 kPa, respectively. Results. Among 66 patients with a successful TE examination at follow-up, 53 patients (80%) had cirrhosis and 13 had (20%) advanced fibrosis (F3) prior to treatment. Median treatment duration was 50.5 months. Among patients with cirrhosis prior to treatment, 26 (49%) had liver stiffness below 11.0 kPa at follow-up, suggesting regression of cirrhosis. Among patients with advanced fibrosis (F3) prior to treatment, 10 (77%) had liver stiffness below 8.1 kPa after treatment, suggesting improvement of fibrosis. Conclusion. Transient elastography examinations demonstrate that prolonged treatment with NUCs in patients with CHB results in low liver stiffness, suggesting regression of fibrosis in a majority of patients with advanced fibrosis or cirrhosis.

AB - Objective. Case reports and short-term clinical trials have suggested that treatment for chronic hepatitis B (CHB) may lead to improvement of cirrhosis. The aim of the present study was to measure liver stiffness in patients diagnosed with advanced fibrosis or cirrhosis prior to prolonged treatment with nucleoside or nucleotide analogs (NUCs) for CHB. Materials and methods. Patients with CHB and advanced fibrosis or cirrhosis prior to treatment with NUCs for at least 1 year were offered inclusion in the study. We measured liver stiffness using transient elastography (TE) at follow-up. TE cut-off levels to Metavir classification for fibrosis stage F2, F3 and F4 were ≥7.2 kPa, ≥8.1, and ≥11.0 kPa, respectively. Results. Among 66 patients with a successful TE examination at follow-up, 53 patients (80%) had cirrhosis and 13 had (20%) advanced fibrosis (F3) prior to treatment. Median treatment duration was 50.5 months. Among patients with cirrhosis prior to treatment, 26 (49%) had liver stiffness below 11.0 kPa at follow-up, suggesting regression of cirrhosis. Among patients with advanced fibrosis (F3) prior to treatment, 10 (77%) had liver stiffness below 8.1 kPa after treatment, suggesting improvement of fibrosis. Conclusion. Transient elastography examinations demonstrate that prolonged treatment with NUCs in patients with CHB results in low liver stiffness, suggesting regression of fibrosis in a majority of patients with advanced fibrosis or cirrhosis.

U2 - 10.3109/00365521.2011.565068

DO - 10.3109/00365521.2011.565068

M3 - Journal article

SN - 0036-5521

VL - 46

SP - 760

EP - 766

JO - Scandinavian Journal of Gastroenterology

JF - Scandinavian Journal of Gastroenterology

IS - 6

ER -

Low liver stiffness among cirrhotic patients with hepatitis B after prolonged treatment with nucleoside analogs

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this